IL246596A0 - ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders - Google Patents
((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disordersInfo
- Publication number
- IL246596A0 IL246596A0 IL246596A IL24659616A IL246596A0 IL 246596 A0 IL246596 A0 IL 246596A0 IL 246596 A IL246596 A IL 246596A IL 24659616 A IL24659616 A IL 24659616A IL 246596 A0 IL246596 A0 IL 246596A0
- Authority
- IL
- Israel
- Prior art keywords
- methylbenzyl
- pyrrolidin
- piperidin
- prodrugs
- hydroxyphenyl
- Prior art date
Links
- UNVYDSCXINFREZ-BHDDXSALSA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-BHDDXSALSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 | |
| PCT/US2015/010552 WO2015105929A1 (en) | 2014-01-09 | 2015-01-08 | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL246596A0 true IL246596A0 (en) | 2016-08-31 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL246596A IL246596A0 (en) | 2014-01-09 | 2016-07-04 | ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (enExample) |
| EP (2) | EP3677578A1 (enExample) |
| JP (1) | JP6629738B2 (enExample) |
| KR (1) | KR102331120B1 (enExample) |
| AR (1) | AR102019A1 (enExample) |
| AU (1) | AU2015204785A1 (enExample) |
| CA (1) | CA2936338A1 (enExample) |
| CL (1) | CL2016001744A1 (enExample) |
| CY (1) | CY1122768T1 (enExample) |
| DK (1) | DK3092223T3 (enExample) |
| EA (1) | EA201691133A1 (enExample) |
| ES (1) | ES2771825T3 (enExample) |
| HR (1) | HRP20200161T1 (enExample) |
| HU (1) | HUE048750T2 (enExample) |
| IL (1) | IL246596A0 (enExample) |
| LT (1) | LT3092223T (enExample) |
| MX (1) | MX2016008715A (enExample) |
| PE (1) | PE20160898A1 (enExample) |
| PL (1) | PL3092223T3 (enExample) |
| PT (1) | PT3092223T (enExample) |
| RS (1) | RS59858B1 (enExample) |
| SG (1) | SG11201605620QA (enExample) |
| SI (1) | SI3092223T1 (enExample) |
| SM (1) | SMT202000094T1 (enExample) |
| TW (1) | TW201612169A (enExample) |
| UY (1) | UY35946A (enExample) |
| WO (1) | WO2015105929A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| AU2016340237A1 (en) * | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| CA3001894A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CA3096145A1 (en) * | 2019-10-11 | 2021-04-11 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| ATE337292T1 (de) | 2000-04-26 | 2006-09-15 | Warner Lambert Co | Trans-n- 4-(4-hydroxyphenyl)cyclohexylö-3- phenylpropionamid als subtyp-selektiver nmda rezeptor antagonist |
| WO2003035641A1 (en) | 2001-10-22 | 2003-05-01 | Shionogi & Co., Ltd. | Novel carbamoylpyrrolidone derivative |
| CN1798744A (zh) | 2003-06-04 | 2006-07-05 | 麦克公司 | 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物 |
| BRPI0415113A (pt) | 2003-10-08 | 2006-11-28 | Pfizer | compostos de lactama condensados |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2170334B1 (en) | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| WO2009064747A2 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en not_active Ceased
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja not_active Expired - Fee Related
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko not_active Expired - Fee Related
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2015-01-08 SM SM20200094T patent/SMT202000094T1/it unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Asketamine for the treatment of depression | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| GB2553919B (en) | Biomass treatment apparatus | |
| IL283948A (en) | Methods for treating depression | |
| IL290955A (en) | Compounds for the treatment of glycogen storage diseases | |
| IL286000A (en) | Asketamine for the treatment of depression | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| SG11201808685SA (en) | Composition for improving brain function for neonates | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL263161B (en) | New compounds for the treatment of parasitic diseases | |
| IL246596A0 (en) | ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| PL3539138T3 (pl) | Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych | |
| SMT202100138T1 (it) | Derivato di 5-metil-6-fenil-4,5-diidr0-2h-piridazin-3-0ne per il trattamento di tumori cerebrali | |
| EP3466354A4 (en) | GREIF TREATMENT INSTRUMENT | |
| EP3104712A4 (en) | Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones | |
| PL3245014T3 (pl) | Sposób rozkładu materiału biomasy zawierającego lignocelulozę | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| HK1225024A1 (en) | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders | |
| HK40107870A (zh) | 用於治疗抑郁症的艾司氯胺酮 | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| GB201715833D0 (en) | Wood treatment process |